Roche breast cancer drug Perjeta rejected by UK cost agency

LONDON, May 20 (Reuters) - Roche's breast cancer

drug Perjeta, or pertuzumab, has been turned down for use on

Britain's state health service, making it the latest in a number

of pricey new cancer...

Read more